Skip to main content
Clinical Trials/NCT04144270
NCT04144270
Unknown
Not Applicable

The Importance of Muscle Function in Patients With Disseminated Bladder Cancer

Rigshospitalet, Denmark1 site in 1 country30 target enrollmentNovember 18, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Urinary Bladder Neoplasm
Sponsor
Rigshospitalet, Denmark
Enrollment
30
Locations
1
Primary Endpoint
Muscle mass
Last Updated
6 years ago

Overview

Brief Summary

This study investigates if reduced muscle mass and muscle function predispose to poor completion of oncological treatment in patients with bladder cancer (including cancer of the renal pelvis, ureter and urethra) and if muscle mass and muscle function change during oncological treatment in these patients. It also evaluates biomarkers for sarcopenia.

Registry
clinicaltrials.gov
Start Date
November 18, 2019
End Date
April 2021
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Lise Hoej Omland

MD

Rigshospitalet, Denmark

Eligibility Criteria

Inclusion Criteria

  • Informed consent
  • Age ≥ 18 år
  • Histologically verified cancer of the renal pelvis, ureter, bladder or urethra regardless of type of histology
  • ECOG performance status 0 - 3
  • Meet the requirements for receiving oncological treatment (neoadjuvant chemotherapy for localized disease, chemotherapy or immunotherapy for disseminated disease).

Exclusion Criteria

  • Age \< 18

Outcomes

Primary Outcomes

Muscle mass

Time Frame: Up to 36 months

We will describe if muscle mass at baseline is correlated to completion of planned systemic oncological treatment

Secondary Outcomes

  • Muscle strength(Up to 36 months)
  • Muscle mass changes during systemic oncological treatment(Up to 36 months)
  • Muscle strength changes during systemic oncological treatment(Up to 36 months)

Study Sites (1)

Loading locations...

Similar Trials